Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Dipool Pharma konsult AB
AB
Active
Org 5594358268
Dagsverkarvägen 6
Temporary employment agency activities and other human resource provisions · NACE 7820
Est. 2023
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 645K
+42% vs 2023
EBITDA margin
79.8%
+29% vs 2023
Equity ratio
75.0%
Financial strength
Net profit 2024
SEK 405K
+27% vs 2023
EBITDA — year on year
SEK millions
1M
1M
1M
0M
0M
0M
2023
1M
+100%
2024
Key figures
Annual report 2024
Revenue
SEK 645K
+42%
EBITDA
SEK 515K
+29%
Net profit
SEK 405K
+27%
Total assets
SEK 997K
+85%
Equity
SEK 748K
+118%
Employees
0
—
Company information
Legal name
Dipool Pharma konsult AB
Org number
5594358268
Legal form
Aktiebolag
NACE code
7820 · Temporary employment agency activities and other human resource provisions
Founded
29 maj 2023
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska bedriva konsultverksamhet inom läkemedelsindustrin och olika apoteksverksamhet genom uthyrning av personal samt headhunting.
Contact
Address
Dagsverkarvägen 6
Email
mnasse352@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Temporary employment agency activities and other human resource provisions
Companies in Upplands-Bro
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2023
1M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2023
1M
2024
Income statement
SEK thousands
Item
2023
2024
Revenue
453
645
Staff expenses
−50
−68
EBITDA
400
515
Depreciation & amort.
—
—
EBIT
400
515
Net financials
−0
−4
Profit before tax
400
511
Tax
−83
−106
Net profit
318
405
Balance sheet
SEK thousands
Item
2023
2024
Total assets
539
997
Equity
343
748
Long-term debt
—
—
Short-term debt
196
249
Total debt
196
249
Financial ratios
5-year trend
EBITDA margin
79.8%
This company
15.8%
Market median
+405% vs market
2023
2024
Equity ratio
75.0%
This company
38.2%
Market median
+96% vs market
2023
2024
Return on equity
54.2%
This company
18.4%
Market median
+195% vs market
2023
2024
Net profit margin
62.8%
This company
8.1%
Market median
+675% vs market
2023
2024
Asset turnover
0.65×
This company
1.12×
Market median
-42% vs market
2023
2024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-05-29 – 2023-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
WA
Wahida Amini
Deputy Board Member
2023
NN
Nasir Nasir
Board of Directors
2023
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Dipool Pharma konsult AB also hold positions in
0
other companies.
Person
Role here
Other companies
Wahida Amini
Deputy Board Member
0 companies
Nasir Nasir
Board of Directors
0 companies